eli lilly glp 1 market share Shows Why the GLP-1 Trade Is Still About Volume, Not Pricing GLP-1 Receptor Agonist Market Size

In 2005, the first GLP-1 receptor agonist, exenatide (marketed as Byetta), was approved by the US Food and Drug Administration and subsequently received European authorisation through the European Medicines Agency (EMA)

ADM prescribing in September 2025 increased slightly compared to June 2025 (+5.2%)

Instead, were seeing a surge of altered, compounded GLP-1 products being marketed aggressively to consumers

Adherence to medication regimens is significantly improved when administration times align with established daily habits

An accumulating body of studies is showing positive potential for using GLP-1s for substance use, said Christian Hendershot, director of clinical research at the USC Institute for Addiction Science, Los Angeles

in the SAVOR-TIMI 53 trial [58]